Featured

Arrowhead To Receive Up To $2 Billion As Part of Novartis Pact For siRNA ARO-SNCA

Cytokinetic’s Aficamten Push Bests SOC In Heart Muscle Disorder

Serina Establishes Registrational Study For SER-252 In PD Under Specific FDA Pathway

Viking’s Stock Craters After Mid-Stage Obesity Trial Data With Oral Drug VK7235

Precigen Scores FDA Approval Of Immunotherapeutic PAPZIMEOS For Rare Respiratory Disease

One Patient Death Due To Kidney Injury In CytomX’s Ongoing Development Of CX-2051

ORIC Reduces Workforce by 20% But Set To Tackle Two Late-Stage Programs In 2026

Novartis’ Win Streak With Ianalumab Continues With Solid ITP Treatment Data Release

Novartis Scores Huge Win In Sjögren’s disease With Dual Action Monoclonal Antibody Ianalumab

Bicycle Reduces 25% Of Staff Amid Second Half Of 2025 Program Updates Expected

Eli Lilly’s Stock Price Drops As Oral GLP-1 Achieves Moderate Weight Loss In Late-Stage Testing

Tern Makes Shift In Pipeline To Cancer Asset TERN-701 As Obesity Space Gets Crowded

BioMarin Gets Rid Of Palynziq Successor To Treat PKU For Lack Of Goal Being Met

Vertex’s Phase 2 Failure Leaves Next-Gen VX-993 Pain Drug On The Chopping Block

Merck’s $3 Billion Cost-Cutting Measure Is First Step For Intended Future Growth

FDA Alters Course On ELEVIDYS Shipping Pause For Ambulatory DMD Patients

CHMP Negative Opinion On ELEVIDYS Brings Further Woes For Sarepta And Its Partner Roche

Rocket Realigns Pipeline Towards Cardiovascular Targeting To Extend Cash Runway

Abivax’s Successful Phase 3 Ulcerative Colitis Trial Shows Obefazimod Differentiation

FDA Rejects Approval Of Replimune’s RP1 For Advanced Melanoma Patients, Type A Meeting Could Possibly Be Next Move

Scroll to Top